title: [Perazine-induced agranulocytosis--case report and discussion].
abstract: A 22-year-old female patient developed agranulocytosis 26 days after starting single agent treatment with perazine. In accordance with the clinical and hematological picture this agranulocytosis is classified as antibody mediated with destruction of peripheral neutrophils. After cessation of perazine treatment and proper therapy of infection the patient recovered within two weeks. The diagnosis of agranulocytosis should be suspected in anyone on neuroleptic treatment who develops fever, malaise or objective evidence of an infection and in neutropenic patients the adequate treatment should be started immediately.
authors.forename: W
authors.initials: W
authors.lastname: Hörner
authors.forename: G
authors.initials: G
authors.lastname: Ehninger
authors.forename: H J
authors.initials: HJ
authors.lastname: Gaertner
mesh_terms: D000328:Adult; D000380:Agranulocytosis / Q000139:chemically induced*; D014150:Antipsychotic Agents / Q000009:adverse effects*; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D009503:Neutropenia / Q000139:chemically induced; D010259:Paranoid Disorders / Q000188:drug therapy*; D010464:Perazine / Q000009:adverse effects* / Q000627:therapeutic use
chemical_list: D014150:Antipsychotic Agents; D010464:Perazine
vernacular_title: Perazininduzierte Agranulozytose--Fallbericht und Diskussion.